Health
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis
SAN FRANCISCO, March 24, 2026--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure.
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/b9977ffb098b0c8c6ce1cd01248e441b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e1n49gYicZh9qeYStOod3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/b9977ffb098b0c8c6ce1cd01248e441b","width":480,"height":480}},"lazy":false},{"type":"text","content":"New AI Care Pathway combines AI echocardiography analysis with coordinated, guideline-based next steps for cardiology and heart failure teams","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"SAN FRANCISCO, March 24, 2026--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure.","length":384,"tagName":"p"},{"type":"text","content":"Cardiac amyloidosis is a progressive condition in which misfolded proteins deposit in the heart muscle, leading to heart failure and poor outcomes if left untreated. There are two primary types of cardiac amyloidosis: the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and light chain amyloidosis (AL). Despite advances in therapy, the majority of patients remain undiagnosed. Those who are diagnosed experience significant delays in treatment due to nonspecific symptoms, fragmented care pathways, and inconsistent recognition of imaging and clinical red flags.1","length":603,"tagName":"p"},{"type":"text","content":""Cardiac amyloidosis is a condition where delayed diagnosis has real consequences in heart failure – earlier identification can fundamentally alter a patient’s trajectory," said Tim Showalter, MD, Chief Medical Officer of Viz.ai. "This partnership is about making early detection actionable. By combining advanced imaging and generative AI with a care coordination platform, we will help clinicians find the right patients earlier and move them swiftly toward appropriate care before the window for meaningful intervention narrows."","length":...